001     126585
005     20240228140834.0
024 7 _ |a 10.1016/j.ccell.2015.10.008
|2 doi
024 7 _ |a pmid:26669487
|2 pmid
024 7 _ |a 1535-6108
|2 ISSN
024 7 _ |a 1878-3686
|2 ISSN
024 7 _ |a altmetric:4844350
|2 altmetric
037 _ _ |a DKFZ-2017-02613
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Giachino, Claudio
|b 0
245 _ _ |a A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes.
260 _ _ |a Cambridge, Mass.
|c 2015
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508414604_6998
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In the brain, Notch signaling maintains normal neural stem cells, but also brain cancer stem cells, indicating an oncogenic role. Here, we identify an unexpected tumor suppressor function for Notch in forebrain tumor subtypes. Genetic inactivation of RBP-Jκ, a key Notch mediator, or Notch1 and Notch2 receptors accelerates PDGF-driven glioma growth in mice. Conversely, genetic activation of the Notch pathway reduces glioma growth and increases survival. In humans, high Notch activity strongly correlates with distinct glioma subtypes, increased patient survival, and lower tumor grade. Additionally, simultaneous inactivation of RBP-Jκ and p53 induces primitive neuroectodermal-like tumors in mice. Hence, Notch signaling cooperates with p53 to restrict cell proliferation and tumor growth in mouse models of human brain tumors.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Basic Helix-Loop-Helix Transcription Factors
|2 NLM Chemicals
650 _ 7 |a Hes5 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin J Recombination Signal Sequence-Binding Protein
|2 NLM Chemicals
650 _ 7 |a Notch1 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Notch2 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Platelet-Derived Growth Factor
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins c-sis
|2 NLM Chemicals
650 _ 7 |a Rbpj protein, mouse
|2 NLM Chemicals
650 _ 7 |a Receptor, Notch1
|2 NLM Chemicals
650 _ 7 |a Receptor, Notch2
|2 NLM Chemicals
650 _ 7 |a Receptors, Notch
|2 NLM Chemicals
650 _ 7 |a Recombinant Proteins
|2 NLM Chemicals
650 _ 7 |a Repressor Proteins
|2 NLM Chemicals
650 _ 7 |a Tumor Suppressor Protein p53
|2 NLM Chemicals
650 _ 7 |a Tumor Suppressor Proteins
|2 NLM Chemicals
650 _ 7 |a platelet-derived growth factor A
|2 NLM Chemicals
700 1 _ |a Boulay, Jean-Louis
|b 1
700 1 _ |a Ivanek, Robert
|b 2
700 1 _ |a Alvarado, Alvaro
|b 3
700 1 _ |a Tostado, Cristobal
|b 4
700 1 _ |a Lugert, Sebastian
|b 5
700 1 _ |a Tchorz, Jan
|b 6
700 1 _ |a Coban, Mustafa
|b 7
700 1 _ |a Mariani, Luigi
|b 8
700 1 _ |a Bettler, Bernhard
|b 9
700 1 _ |a Lathia, Justin
|b 10
700 1 _ |a Frank, Stephan
|b 11
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 12
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 13
|u dkfz
700 1 _ |a Taylor, Verdon
|b 14
773 _ _ |a 10.1016/j.ccell.2015.10.008
|g Vol. 28, no. 6, p. 730 - 742
|0 PERI:(DE-600)2074034-7
|n 6
|p 730 - 742
|t Cancer cell
|v 28
|y 2015
|x 1535-6108
909 C O |o oai:inrepo02.dkfz.de:126585
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER CELL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b CANCER CELL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21